CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionThe role of drug transporters in the kidney: lessons from tenofovirStructural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transportersPredictive modeling of in vivo response to gemcitabine in pancreatic cancerPharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studiesNucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA-methyltransferase inhibitors.PharmGKB summary: gemcitabine pathwayDifferential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoproteinLow expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent mannerThe MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Drugs in preclinical and early-stage clinical development for pancreatic cancer.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.Role of solute carrier transporters in pancreatic cancer: a review.MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.Noncoding RNAs in Therapeutic Resistance of Cancer.Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.Harnessing Solute Carrier Transporters for Precision Oncology.Integrative genome-wide analysis of the determinants of RNA splicing in kidney renal clear cell carcinoma.SET contributes to the epithelial-mesenchymal transition of pancreatic cancer.Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.Pancreatic Cancer Chemoresistance to Gemcitabine.The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.Emerging Roles of Nucleoside Transporters.
P2860
Q24273350-610E7F6C-180F-478F-B065-052644E8E5B3Q26866489-70B25DF6-3B8C-4AA6-94BD-7E3A31AE6F88Q27684896-163D2527-B0D8-41CA-8C54-2E3BF8265F50Q28533633-81449F42-1436-4459-89EE-3751270135C8Q28535154-6CBD248B-D100-49EF-AB38-146F684205F8Q34025097-458B7644-595C-4B51-8AC8-91078BDF12E6Q34435450-CC87F694-0795-48D6-8CD9-A0A1BF37A4BEQ34555685-93D16CF0-F419-4F3F-A2BF-D19B72445FD0Q34861855-C48E1A59-7173-4761-9AE7-4B560D88E441Q35066350-67B8A368-315F-4A85-88FF-3B85D76A9263Q35612005-C1CABC5B-4975-413F-A105-2B9D47AAA915Q35735278-7D4CFE03-3580-439F-B0BB-AF861709EADBQ35768413-05913501-7182-4EC1-89F8-3539579F51A1Q36342657-A24CC2C7-202A-48A2-849B-760EFF2D7724Q36907164-E8A6C448-44DF-4298-8659-9DFAC7DFE807Q37605606-D4E3BEF6-0CA8-4002-8665-9B31ED1624E1Q37713632-DB11E509-E6E6-4654-A90D-8CF3521D775CQ37955222-1791D553-32E1-4C2D-82AE-060B0CC6F01AQ37973133-D5716170-B1E9-4C52-8ED8-655C24D2B3C5Q37994505-28E96205-F7AF-44CB-906E-694B7BFEE128Q38058785-94099D17-7EB8-4F4F-8C3D-C77269996439Q38236028-1D1B0F34-783D-4A69-98BA-55093A0A6B5FQ38804384-7CA11E59-EDEB-4A12-A23F-A3CAFF199101Q38885495-167F1DA2-A3EC-4F72-BCB3-10CEB0D82940Q39101616-7DD281C7-E1B3-40A8-BFBE-76425F296D14Q39204754-30B8B9BD-D32F-4BE7-AC89-35A863082C22Q41577524-937A4786-45DC-4475-B4A2-4BFC520A9C39Q42100343-748178AB-9070-4E38-ACEC-3C29749D8670Q42717833-1EFA2D22-584D-4B77-9753-A41B5AC01F1DQ47130749-C42C5550-3F2D-46A5-AB08-DE33D7CE8BC4Q47135556-1F343FE0-D9DB-4141-B625-D3FAE6CDC4BAQ47808300-55F3D889-52DF-45B4-9A56-89286AA0578EQ47830761-98F349CE-6F86-4E45-98E0-E6BAFA84AA0CQ49388105-6799EA62-489B-4A94-821D-4E3E85CEB729Q50569337-F94D1959-4694-40D2-8F28-43E013101B10Q55384452-9C92219B-F37F-4B23-A40B-6182BAE587A0
P2860
CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
CNT1 expression influences pro ...... istant pancreatic cancer cells
@ast
CNT1 expression influences pro ...... istant pancreatic cancer cells
@en
CNT1 expression influences pro ...... istant pancreatic cancer cells
@nl
type
label
CNT1 expression influences pro ...... istant pancreatic cancer cells
@ast
CNT1 expression influences pro ...... istant pancreatic cancer cells
@en
CNT1 expression influences pro ...... istant pancreatic cancer cells
@nl
prefLabel
CNT1 expression influences pro ...... istant pancreatic cancer cells
@ast
CNT1 expression influences pro ...... istant pancreatic cancer cells
@en
CNT1 expression influences pro ...... istant pancreatic cancer cells
@nl
P2093
P2860
P1433
P1476
CNT1 expression influences pro ...... istant pancreatic cancer cells
@en
P2093
Bhavi Patel
Dylan Lovin
Rajgopal Govindarajan
Sau Wai Hung
Yangzom D Bhutia
P2860
P304
P356
10.1158/0008-5472.CAN-10-2736
P407
P577
2011-02-22T00:00:00Z